July 25, ,2013 : Bharat Book Bureau presents the new report, on 'Vaccine Partnering Terms and Agreements' The report provides a detailed understanding and analysis of how and why companies enter vaccine partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report also includes adjuvant deals and alliances.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.
This report contains over 1,400 links to online copies of actual vaccine deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
The initial chapters of this report provide an orientation of vaccine dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in vaccine dealmaking since 2007, including details of average headline, upfront, milestone and royalty terms.
Chapter 3 provides a review of the leading vaccine deals since 2007. Deals are listed by headline value, signed by big pharma, big biotech, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of vaccine deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 5 provides a comprehensive listing of the top big biotech companies with a brief summary followed by a comprehensive listing of vaccine deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
TABLE OF CONTENTS
Chapter 1 – Introduction
Chapter 2 – Trends in vaccine dealmaking
2.2. Vaccine partnering over the years
2.3. Bigpharma vaccine dealmaking activity
2.4. Big biotech vaccine dealmaking activity
2.5. Most active in vaccine partnering
2.6. Vaccine partnering by deal type
2.7. Vaccine partnering by disease type
2.8. Average deal terms for vaccine partnering
2.8.1 Vaccine partnering headline values
2.8.2 Vaccine deal upfront payments
2.8.3 Vaccine deal milestone payments
2.8.4 Vaccine royalty rates
2.9. The anatomy of vaccine partnering
2.9. The anatomy of a vaccine deal
2.9.a. Case study 1: Stemline Therapeutics- University of Pittsburgh: March 2012
2.9.b. Case study 2: Agenus Bio- NewVac: December 2011
Chapter 3 – Leading vaccine deals
3.2. Top vaccine deals by value
3.3. Top vaccine deals involving big pharma
3.4. Top vaccine deals involving big biotech
Chapter 4 – Bigpharma vaccine deals
4.2. How to use bigpharma vaccine partnering deals
4.3. Big pharma vaccine partnering company profiles
Johnson & Johnson
Kyowa Hakko Kirin
Merck & Co
Purdue Research Foundation
Chapter 5 – Big biotech vaccine deals
5.2. How to use big biotech partnering deals
5.3. Bigbiotech vaccine partnering company profiles
Chapter 6 – Vaccine dealmaking directory
6.2. Company A-Z
6.3. By stage of development
6.4. By deal type
6.5. By therapy area
Chapter 7 – Vaccine dealmaking directory but technology type
Chapter 8 – Vaccine partnering resource center
8.1. Online vaccine partnering
8.2. Vaccine partnering events
8.3. Further reading on vaccine dealmaking
About Wildwood Ventures
Recent titles from CurrentPartnering
Order Form – Reports
For more information kindly visit : http://www.bharatbook.com/healthcare-market-research-reports/vaccine-partnering-terms-and-agreements.html
About Bharat Book Bureau:
Bharat Book Bureau is the leading market research information provider for market research reports, , company profiles, industry analysis , country reports , business reports, newsletters and online databases Bharat Book Bureau provides over a million reports from more than 400 publishers around the globe. We cover sectors starting from Aeronautics to Zoology.
In case the reports don’t match your requirement then we can do a specialized Custom Research for you. Our multifarious capabilities, cross-sector expertise and detailed knowledge of various markets, put us in a unique position to take up Custom Research demands of yourself.
Contact us at :
Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Toll Free No for USA/Canada : 1-866-279-8368
Call UK +44 7405 208461
Follow us on twitter: https://twitter.com/researchbook
Follow us on linkedin : http://www.linkedin.com/company/bharat-book-bureau
Our Blog : http://blog.bharatbook.com/
Bharat Book Bureau, the leading market research information aggregator provides market research reports, company profiles, country reports, newsletters, and online databases for the past twenty four years to corporate, consulting firms, academic institutions, government departments, agencies etc., globally, including India. Our market research reports help global companies to know different market before starting up business / expanding in different countries across the world.